FUNCtion ALS: Aiming to Restore UNC13A Function in People Living With ALS
Recruiting now · Phase 1/Phase 2 · Has a placebo group
Conditions studied: Amyotrophic Lateral Sclerosis
In brief
The FUNCtion Amyotrophic Lateral Sclerosis (ALS) trial is a randomized, double-blind, placebo-controlled Phase 1/2 trial to evaluate the safety and tolerability of TRCN-1023 in adults living with ALS. TRCN-1023 is an investigational medicine given as a single injection into the fluid surrounding the spine (intrathecal injection). The trial will also assess how the body processes the drug and whether it shows early signs of benefit over 24 weeks.
Key facts
- Study ID
- NCT07674667
- Run by
- Trace Neuroscience, Inc.
- People needed
- 30
- Starts
- 2026-08-01
- Expected to finish
- 2027-09-01
- Last updated by the study team
- 2026-08-05
Who can join
Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.
Where it is running
- TUM Klinikum Rechts der Isar — Munich, Germany (enrolling)
- University Medical Center Utrecht — Utrecht, Netherlands (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.